Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | TNNI3K | Q59H18 | 8/20 | 0.51 |
| ▸ | MAP2K7 | O14733 | 5/20 | 0.47 |
| ▸ | RAF1 | P04049 | 5/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780386 | 0.94 | KDR (0.49) | KDRTNNI3KMAP2K7RAF1MAPK14 | |
| SCHEMBL2778534 | 0.93 | KDR (0.48) | KDRTNNI3KMAP2K7RAF1MAPK14 | |
| SCHEMBL2778309 | 0.89 | KDR (0.44) | KDRTNNI3KMAP2K7NOTUMMAPK14 | |
| SCHEMBL2796677 | 0.85 | KDR (0.45) | KDRNOTUM | |
| SCHEMBL2779088 | 0.84 | NOTUM (0.45) | NOTUM | |
| SCHEMBL2777587 | 0.83 | NOTUM (0.44) | KDRTNNI3KNOTUMMAPK14BRAF | |
| SCHEMBL12972282 | 0.83 | KDR (0.55) | KDRTNNI3KMAP2K7RAF1MAPK14 | |
| SCHEMBL2708240 | 0.82 | KDR (0.48) | KDRTNNI3KMAP2K7RAF1 | |
| SCHEMBL2777729 | 0.82 | SMN1; SMN2 (0.41) | KDRMAP2K7NOTUM | |
| SCHEMBL2777726 | 0.81 | NOTUM (0.43) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-7652022-B2 | N-(4-(4-(4-hydroxyphenylamino)-pyrimidin-6-yl)-oxyphenyl)-N'-(3-trifluoromethylphenyl)-urea; | NOVARTIS AG (CH) | 2010-01-26 | — | — | US | disclosed |
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | disclosed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885TNNI3K 270/4885MAP2K7 121/4885 |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | KDR 3898/4885TNNI3K 340/4885MAP2K7 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.